Table 2.
Analysis of the Clinical Data of Patients in the Two Groups [n (%)]
| Factor | Control Group (n=55) | Observation Group (n=65) | X2 | P-value | |
|---|---|---|---|---|---|
| Sex | 0.881 | 0.348 | |||
| Female | 40 (72.73) | 52 (80.00) | |||
| Male | 15 (27.27) | 13 (20.00) | |||
| Age | 0.129 | 0.720 | |||
| ≥65 years | 39 (70.91) | 48 (73.85) | |||
| <65 years | 16 (29.09) | 17 (26.15) | |||
| Pathological type | 0.319 | 0.572 | |||
| Squamous cell carcinoma | 50 (90.91) | 57 (87.69) | |||
| Adenocarcinoma | 5 (9.09) | 8 (12.31) | |||
| Clinical stages | 5.124 | 0.077 | |||
| IIIA | 10 (18.18) | 8 (12.31) | |||
| IIIB | 18 (32.73) | 12 (18.46) | |||
| IIV | 27 (49.09) | 45 (69.23) | |||
| Brain metastases | 1.400 | 0.237 | |||
| Yes | 8 (14.55) | 15 (23.08) | |||
| No | 47 (85.45) | 50 (76.92) | |||
| Smoking history | 1.907 | 0.167 | |||
| Yes | 42 (76.36) | 56 (86.15) | |||
| No | 13 (23.64) | 9 (13.85) | |||
| EGFR mutation | 2.553 | 0.110 | |||
| Yes | 40 (72.73) | 55 (84.62) | |||
| No | 15 (27.27) | 10 (15.38) | |||
| Body weight change | 0.727 | 0.394 | |||
| >5% | 10 (18.18) | 16 (24.62) | |||
| ≤5% | 45 (81.82) | 49 (75.38) | |||
| ECOG score | 0.311 | 0.577 | |||
| 0 | 16 (29.09) | 22 (33.85) | |||
| 1 | 39 (70.91) | 43 (66.15) |
Abbreviations: EGFR, epidermal growth factor receptor; ECOG, Eastern Cooperative Oncology Group.